Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jun 15, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
21.2%
-43.4% vs 52w high · -4.2% 1mo
Price (last ~year)
Novo Nordisk (NVO) reported 24.0% year-over-year revenue growth and 67.1% earnings growth, though the company recently disclosed a cyberattack involving unauthorized access to clinical trial data. While the firm secured UK approval for its Wegovy pill, it faces intensifying competition in the weight-loss market. The stock, which has gained 21.2% over the last three months, currently trades at a 10.37 P/E ratio with a market capitalization of $194.35 billion.
Valuation
- Market cap
- $194.35B
- P/E
- 10.37
- PEG
- 3.206
- P/B
- 6.2
- P/S
- 0.593
- EV/EBITDA
- 7.77
- Beta
- 0.349
- Analyst target
- $47.29
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $43.88
- 1-month
- -4.2%
- 3-month
- +21.2%
- RSI (14)
- 46
- vs SMA200
- -7.0%
- 52-wk position
- 21.2% -43.4% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Neutral Novo Nordisk comeback stirs as Wegovy pill wins UK approval · 2026-06-12
- Somewhat-Bearish Novo Nordisk identifies unauthorised data access from trials · 2026-06-12
- Neutral Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About · 2026-06-12
- Neutral Novo Nordisk reports cyberattack as UK gives Wegovy pill the nod · 2026-06-12
- Somewhat-Bearish Patient information exposed in breach, says Novo Nordisk · 2026-06-12
- Bearish Pharma giant Novo Nordisk discloses breach of clinical trials data · 2026-06-12
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)